Feasibility, long‐term safety, and immune monitoring of regulatory T cell therapy in living donor kidney transplant recipients-Reference-Cited by-同舟云学术

Feasibility, long‐term safety, and immune monitoring of regulatory T cell therapy in living donor kidney transplant recipients

Published:2021-02-02 Issue:4 Volume:21 Page:1603-1611
ISSN:1600-6135
Container-title:American Journal of Transplantation
language:en
Short-container-title:Am J Transplant

Author:

Harden Paul N.¹^ORCID,Game David S.²,Sawitzki Birgit³,Van der Net Jeroen B.¹,Hester Joanna⁴,Bushell Andrew⁴,Issa Fadi⁴,Brook Matthew O.¹⁴,Alzhrani Alaa⁴,Schlickeiser Stephan³,Scotta Cristiano⁵,Petchey William¹,Streitz Mathias³,Blancho Gilles⁶,Tang Quizhi⁷,Markmann James⁸^ORCID,Lechler Robert I.⁵,Roberts Ian S. D.⁹,Friend Peter J.¹,Hilton Rachel²,Geissler Edward K.¹⁰,Wood Kathryn J.⁴,Lombardi Giovanna⁵

Affiliation:

1. Oxford Transplant Centre Oxford University Hospitals NHS Foundation Trust Oxford UK

2. Department of Transplantation Guys and St Thomas’s Hospital NHS Trust London UK

3. Institute of Medical Immunology Charite University of Medicine Berlin Germany

4. Transplantation Research Immunology Group University of Oxford Oxford UK

5. Peter Gorer Department of Immunobiology School of Immunology and Microbial ScienceKings College London London UK

6. Centre of Research in Transplantation and Immunology Nantes University Nantes France

7. UCSF Transplantation Research Lab Department of Surgery University of California San Francisco California

8. Center for Transplantation Sciences Massachusetts General Hospital Boston Massachusetts

9. Department of Pathology Oxford University Hospitals NHS Foundation Trust Oxford UK

10. Department of Surgery Division of Experimental Surgery University of Regensburg Regensburg Germany

Funder

National Institute for Health Research

Publisher

Wiley

Subject

Pharmacology (medical),Transplantation,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ajt.16395

Reference19 articles.

1. Cell Therapy in Organ Transplantation: Our Experience on the Clinical Translation of Regulatory T Cells

2. A Phase I Clinical Trial with Ex Vivo Expanded Recipient Regulatory T cells in Living Donor Kidney Transplants

3. Applicability, safety, and biological activity of regulatory T cell therapy in liver transplantation

4. Polyclonal Regulatory T Cell Therapy for Control of Inflammation in Kidney Transplants

5. Cardiovascular Disease After Kidney Transplant

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Application of spatial-omics to the classification of kidney biopsy samples in transplantation;Nature Reviews Nephrology;2024-07-04

2. Late Treatment With Autologous Expanded Regulatory T-cell Therapy After Alemtuzumab Induction Is Safe and Facilitates Immunosuppression Minimization in Living Donor Renal Transplantation;Transplantation;2024-06-07

3. Relationship between the microenvironment and survival in kidney transplantation: a bibliometric analysis from 2013 to 2023;Frontiers in Immunology;2024-03-26

4. Antibody-Suppressor CXCR5+CD8+ T Cells Are More Potent Regulators of Humoral Alloimmunity after Kidney Transplant in Mice Compared to CD4+ Regulatory T Cells;The Journal of Immunology;2024-03-22

5. Harnessing regulatory T cells to establish immune tolerance;Science Translational Medicine;2024-03-13